메뉴 건너뛰기




Volumn 94, Issue 9, 2019, Pages 1007-1014

A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; HEMOGLOBIN; IRON ISOMALTOSE; IRON SACCHARATE; MONOFERRIC; TRANSFERRIN; DISACCHARIDE; FERRIC ION;

EID: 85069823599     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.25564     Document Type: Article
Times cited : (68)

References (32)
  • 1
    • 84928603336 scopus 로고    scopus 로고
    • European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases
    • Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211-222.
    • (2015) J Crohns Colitis , vol.9 , pp. 211-222
    • Dignass, A.U.1    Gasche, C.2    Bettenworth, D.3
  • 2
    • 85069856223 scopus 로고    scopus 로고
    • KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease., Accessed May 22, 2019
    • KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. 2012. https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf. Accessed May 22, 2019.
    • (2012)
  • 3
    • 38049048044 scopus 로고    scopus 로고
    • Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases
    • Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13:1545-1553.
    • (2007) Inflamm Bowel Dis , vol.13 , pp. 1545-1553
    • Gasche, C.1    Berstad, A.2    Befrits, R.3
  • 4
    • 84973130364 scopus 로고    scopus 로고
    • Iron management in chronic kidney disease: conclusions from a “kidney disease: improving global outcomes” (KDIGO) controversies conference
    • Macdougall IC, Bircher AJ, Eckardt KU, et al. Iron management in chronic kidney disease: conclusions from a “kidney disease: improving global outcomes” (KDIGO) controversies conference. Kidney Int. 2016;89:28-39.
    • (2016) Kidney Int , vol.89 , pp. 28-39
    • Macdougall, I.C.1    Bircher, A.J.2    Eckardt, K.U.3
  • 5
    • 85000968659 scopus 로고    scopus 로고
    • Complement activation-related pseudo-allergy: a fresh look at hypersensitivity reactions to intravenous iron
    • Macdougall IC, Vernon K. Complement activation-related pseudo-allergy: a fresh look at hypersensitivity reactions to intravenous iron. Am J Nephrol. 2017;45:60-62.
    • (2017) Am J Nephrol , vol.45 , pp. 60-62
    • Macdougall, I.C.1    Vernon, K.2
  • 6
    • 85001073675 scopus 로고    scopus 로고
    • Distinct in vitro complement activation by various intravenous iron preparations
    • Hempel JC, Poppelaars F, Gaya da Costa M, et al. Distinct in vitro complement activation by various intravenous iron preparations. Am J Nephrol. 2017;45:49-59.
    • (2017) Am J Nephrol , vol.45 , pp. 49-59
    • Hempel, J.C.1    Poppelaars, F.2    Gaya da Costa, M.3
  • 7
    • 84908459097 scopus 로고    scopus 로고
    • Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management
    • Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99:1671-1676.
    • (2014) Haematologica , vol.99 , pp. 1671-1676
    • Rampton, D.1    Folkersen, J.2    Fishbane, S.3
  • 8
    • 34247615981 scopus 로고    scopus 로고
    • Clinical update: intravenous iron for anaemia
    • Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet. 2007;369:1502-1504.
    • (2007) Lancet , vol.369 , pp. 1502-1504
    • Auerbach, M.1    Ballard, H.2    Glaspy, J.3
  • 9
    • 85031284867 scopus 로고    scopus 로고
    • Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose for the treatment of iron deficiency anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions
    • Adkinson NF, Strauss WE, Bernard K, Kaper RF, Macdougall IC, Krop JS. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose for the treatment of iron deficiency anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions. J Blood Med. 2017;8:155-163.
    • (2017) J Blood Med , vol.8 , pp. 155-163
    • Adkinson, N.F.1    Strauss, W.E.2    Bernard, K.3    Kaper, R.F.4    Macdougall, I.C.5    Krop, J.S.6
  • 10
    • 85042412026 scopus 로고    scopus 로고
    • Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial
    • Adkinson NF, Strauss WE, Macdougall IC, et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial. Am J Hematol. 2018;93:683-690.
    • (2018) Am J Hematol , vol.93 , pp. 683-690
    • Adkinson, N.F.1    Strauss, W.E.2    Macdougall, I.C.3
  • 11
    • 85059183416 scopus 로고    scopus 로고
    • Iron therapy in heart failure: ready for primetime
    • Mordi IR, Tee A, Lang CC. Iron therapy in heart failure: ready for primetime. Card Fail Rev. 2018;4:28-32.
    • (2018) Card Fail Rev , vol.4 , pp. 28-32
    • Mordi, I.R.1    Tee, A.2    Lang, C.C.3
  • 12
    • 79960617268 scopus 로고    scopus 로고
    • A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications
    • Jahn MR, Andreasen HB, Futterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011;78:480-491.
    • (2011) Eur J Pharm Biopharm , vol.78 , pp. 480-491
    • Jahn, M.R.1    Andreasen, H.B.2    Futterer, S.3
  • 13
    • 77951634849 scopus 로고    scopus 로고
    • Novel biomarkers, oxidative stress, and the role of labile iron toxicity in cardiopulmonary bypass-associated acute kidney injury
    • Haase M, Bellomo R, Haase-Fielitz A. Novel biomarkers, oxidative stress, and the role of labile iron toxicity in cardiopulmonary bypass-associated acute kidney injury. J Am Coll Cardiol. 2010;55:2024-2033.
    • (2010) J Am Coll Cardiol , vol.55 , pp. 2024-2033
    • Haase, M.1    Bellomo, R.2    Haase-Fielitz, A.3
  • 14
    • 85011614591 scopus 로고    scopus 로고
    • Reactive oxygen species: a key hallmark of cardiovascular disease
    • Panth N, Paudel KR, Parajuli K. Reactive oxygen species: a key hallmark of cardiovascular disease. Adv Med. 2016;2016:9152732.
    • (2016) Adv Med , vol.2016 , pp. 9152732
    • Panth, N.1    Paudel, K.R.2    Parajuli, K.3
  • 15
    • 79953284567 scopus 로고    scopus 로고
    • Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A pilot study
    • Hildebrandt PR, Bruun NE, Nielsen OW, et al. Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A pilot study. Transfus Altern Transfus Med. 2010;11:131-137.
    • (2010) Transfus Altern Transfus Med , vol.11 , pp. 131-137
    • Hildebrandt, P.R.1    Bruun, N.E.2    Nielsen, O.W.3
  • 16
    • 79958169242 scopus 로고    scopus 로고
    • Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease
    • Wikstrom B, Bhandari S, Barany P, et al. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. J Nephrol. 2011;24:589-596.
    • (2011) J Nephrol , vol.24 , pp. 589-596
    • Wikstrom, B.1    Bhandari, S.2    Barany, P.3
  • 17
    • 84937150491 scopus 로고    scopus 로고
    • A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease
    • Reinisch W, Altorjay I, Zsigmond F, et al. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. Scand J Gastroenterol. 2015;50:1226-1233.
    • (2015) Scand J Gastroenterol , vol.50 , pp. 1226-1233
    • Reinisch, W.1    Altorjay, I.2    Zsigmond, F.3
  • 18
    • 84889690772 scopus 로고    scopus 로고
    • A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED)
    • Reinisch W, Staun M, Tandon RK, et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol. 2013;108:1877-1888.
    • (2013) Am J Gastroenterol , vol.108 , pp. 1877-1888
    • Reinisch, W.1    Staun, M.2    Tandon, R.K.3
  • 19
    • 84941598898 scopus 로고    scopus 로고
    • Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial)
    • Johansson PI, Rasmussen AS, Thomsen LL. Intravenous iron isomaltoside 1000 (Monofer) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial). Vox Sang. 2015;109:257-266.
    • (2015) Vox Sang , vol.109 , pp. 257-266
    • Johansson, P.I.1    Rasmussen, A.S.2    Thomsen, L.L.3
  • 20
    • 84940645637 scopus 로고    scopus 로고
    • A randomized, open-label trial of iron isomaltoside 1000 (Monofer) compared with iron sucrose (Venofer) as maintenance therapy in haemodialysis patients
    • Bhandari S, Kalra PA, Kothari J, et al. A randomized, open-label trial of iron isomaltoside 1000 (Monofer) compared with iron sucrose (Venofer) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant. 2015;30:1577-1589.
    • (2015) Nephrol Dial Transplant , vol.30 , pp. 1577-1589
    • Bhandari, S.1    Kalra, P.A.2    Kothari, J.3
  • 21
    • 84965179566 scopus 로고    scopus 로고
    • A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia
    • Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant. 2016;31:646-655.
    • (2016) Nephrol Dial Transplant , vol.31 , pp. 646-655
    • Kalra, P.A.1    Bhandari, S.2    Saxena, S.3
  • 22
    • 84963682363 scopus 로고    scopus 로고
    • A randomized, noninferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy, the profound trial
    • Birgegard G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M. A randomized, noninferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy, the profound trial. Pharmacotherapy. 2016;36:402-414.
    • (2016) Pharmacotherapy , vol.36 , pp. 402-414
    • Birgegard, G.1    Henry, D.2    Glaspy, J.3    Chopra, R.4    Thomsen, L.L.5    Auerbach, M.6
  • 23
    • 84975266509 scopus 로고    scopus 로고
    • High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23
    • Dahlerup JF, Jacobsen BA, van der Woude J, Bark LA, Thomsen LL, Lindgren S. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. Scand J Gastroenterol. 2016;51:1332-1338.
    • (2016) Scand J Gastroenterol , vol.51 , pp. 1332-1338
    • Dahlerup, J.F.1    Jacobsen, B.A.2    van der Woude, J.3    Bark, L.A.4    Thomsen, L.L.5    Lindgren, S.6
  • 24
    • 85013158265 scopus 로고    scopus 로고
    • Single-dose intravenous iron infusion or oral iron for treatment of fatigue after postpartum haemorrhage: a randomized controlled trial
    • Holm C, Thomsen LL, Norgaard A, Langhoff-Roos J. Single-dose intravenous iron infusion or oral iron for treatment of fatigue after postpartum haemorrhage: a randomized controlled trial. Vox Sang. 2017;112:219-228.
    • (2017) Vox Sang , vol.112 , pp. 219-228
    • Holm, C.1    Thomsen, L.L.2    Norgaard, A.3    Langhoff-Roos, J.4
  • 25
    • 85007426093 scopus 로고    scopus 로고
    • Single-dose intravenous iron infusion versus red blood cell transfusion for the treatment of severe postpartum anaemia: a randomized controlled pilot study
    • Holm C, Thomsen LL, Norgaard A, Langhoff-Roos J. Single-dose intravenous iron infusion versus red blood cell transfusion for the treatment of severe postpartum anaemia: a randomized controlled pilot study. Vox Sang. 2017;112:122-131.
    • (2017) Vox Sang , vol.112 , pp. 122-131
    • Holm, C.1    Thomsen, L.L.2    Norgaard, A.3    Langhoff-Roos, J.4
  • 26
    • 85041515292 scopus 로고    scopus 로고
    • Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial
    • Gybel-Brask M, Seeberg J, Thomsen LL, Johansson PI. Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial. Transfusion. 2018;58:974-981.
    • (2018) Transfusion , vol.58 , pp. 974-981
    • Gybel-Brask, M.1    Seeberg, J.2    Thomsen, L.L.3    Johansson, P.I.4
  • 27
    • 85011025181 scopus 로고    scopus 로고
    • A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia
    • Derman R, Roman E, Modiano MR, Achebe MM, Thomsen LL, Auerbach M. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol. 2017;92:286-291.
    • (2017) Am J Hematol , vol.92 , pp. 286-291
    • Derman, R.1    Roman, E.2    Modiano, M.R.3    Achebe, M.M.4    Thomsen, L.L.5    Auerbach, M.6
  • 29
    • 84947431101 scopus 로고    scopus 로고
    • Comparative risk of anaphylactic reactions associated with intravenous iron products
    • Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA. 2015;314:2062-2068.
    • (2015) JAMA , vol.314 , pp. 2062-2068
    • Wang, C.1    Graham, D.J.2    Kane, R.C.3
  • 30
    • 84983311761 scopus 로고    scopus 로고
    • Safety of intravenous iron use in chronic kidney disease
    • Kalra PA, Bhandari S. Safety of intravenous iron use in chronic kidney disease. Curr Opin Nephrol Hypertens. 2016;25:529-535.
    • (2016) Curr Opin Nephrol Hypertens , vol.25 , pp. 529-535
    • Kalra, P.A.1    Bhandari, S.2
  • 31
    • 84961176944 scopus 로고    scopus 로고
    • Efficacy and safety of iron isomaltoside (Monofer) in the management of patients with iron deficiency anemia
    • Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside (Monofer) in the management of patients with iron deficiency anemia. Int J Nephrol Renovasc Dis. 2016;9:53-64.
    • (2016) Int J Nephrol Renovasc Dis , vol.9 , pp. 53-64
    • Kalra, P.A.1    Bhandari, S.2
  • 32
    • 85044230148 scopus 로고    scopus 로고
    • Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage
    • Holm C, Thomsen LL, Langhoff-Roos J. Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage. J Matern Fetal Neonatal Med. 2019;32:2797-2804.
    • (2019) J Matern Fetal Neonatal Med , vol.32 , pp. 2797-2804
    • Holm, C.1    Thomsen, L.L.2    Langhoff-Roos, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.